Airsculpt Technologies, Inc. Stock Price, News & Analysis

AirSculpt Technologies, a provider of premium body contouring procedures, has successfully closed its previously announced public offering of 3,160,000 shares of common stock, with underwriters fully exercising their option for an additional 474,000 shares. The offering generated approximately $13.8 million in proceeds after estimated expenses. Leerink Partners served as the sole bookrunner. The company plans to use the majority of proceeds to prepay a portion of its outstanding debt under its existing credit agreement, with the remainder allocated for general corporate purposes, working capital, and business opportunities. The offering was conducted under a shelf registration statement that became effective on March 24, 2025.

AirSculpt Technologies (NASDAQ:AIRS), a national provider of premium body contouring procedures, has announced the pricing of its public offering of 3,160,000 common stock shares at $3.80 per share, aiming to raise $12.0 million before expenses. The company has granted the underwriter, Leerink Partners, a 30-day option to purchase up to 474,000 additional shares at the same price. The offering is expected to close around June 11, 2025. AirSculpt plans to use most of the proceeds to prepay a portion of its outstanding debt under its existing credit agreement, with the remainder allocated for general corporate purposes, including working capital and business opportunities.

AirSculpt Technologies (NASDAQ:AIRS), a premium body contouring procedures provider, has announced a public offering of 3,160,000 shares of common stock, with an additional 30-day option for underwriters to purchase up to 474,000 shares. Vesey Street Capital Partners, the company's largest stockholder, has expressed interest in purchasing up to $4.0 million in shares, though this is not a binding commitment. The company plans to use the proceeds to prepay a portion of its outstanding debt under its existing credit agreement and for general corporate purposes. Leerink Partners is serving as the sole bookrunner for the offering, which is being conducted under a shelf registration statement that became effective on March 24, 2025.

AirSculpt Technologies (NASDAQ:AIRS) reported Q1 2025 results showing significant declines across key metrics. Revenue dropped 17.3% to $39.4 million from $47.6 million in Q1 2024, while case volume decreased 17.9% to 3,076 cases. The company posted a net loss of $2.8 million compared to a $6.0 million profit in the prior year, and Adjusted EBITDA fell to $3.8 million from $7.3 million. Despite challenges, CEO Yogi Jashnani highlighted progress in cost reduction initiatives and new marketing strategies. The company provided FY2025 guidance projecting revenue of $160-170 million and Adjusted EBITDA of $16-18 million. AirSculpt is piloting skin tightening as a standalone offering and implementing expanded financing options to drive growth. The company maintained $5.6 million in cash and remained compliant with bank covenants.

AirSculpt Technologies (NASDAQ: AIRS), a premium body contouring procedures provider, has scheduled its first quarter 2025 financial results announcement for Friday, May 2, 2025. The company will release results before market open, followed by a conference call at 8:00 a.m. Eastern Time.

Investors can join the conference call via telephone by dialing 1-877-407-9716 (domestic) or 1-201-493-6779 (international) with conference ID 13753206. Alternatively, a live webcast will be available through the investor relations section of AirSculpt's website, with replay access for approximately 90 days.

AirSculpt Technologies (NASDAQ:AIRS) reported challenging fourth quarter and full year 2024 results, showing significant declines across key metrics. Q4 revenue dropped 17.7% to $39.2 million, with case volume declining 16.7% to 3,064 cases. The company posted a Q4 net loss of $5.0 million.

For full year 2024, revenue decreased 7.9% to $180.4 million, with case volume falling 6.0% to 14,036. Net loss widened to $8.3 million from $4.5 million in 2023, while Adjusted EBITDA declined to $20.7 million from $43.2 million.

The company has implemented a cost reduction program targeting $3 million in annual savings and has paused new center openings. With $8.2 million in cash and operating cash flow of $11.4 million for 2024, AirSculpt has secured additional covenant relief from lenders to support its transformation efforts.

AirSculpt Technologies (NASDAQ: AIRS), a premium body contouring procedures provider, has scheduled its fourth quarter 2024 financial results announcement for Friday, March 14, 2025, before market open.

The company will host a conference call at 8:30 a.m. Eastern Time on the same day. Investors can access the call through toll-free domestic (1-877-407-9716) or international (1-201-493-6779) numbers using conference ID 13751643. A live webcast will be available through the investor relations section of AirSculpt's website, with a replay accessible for approximately 90 days.

AirSculpt Technologies (NASDAQ: AIRS) has updated its fiscal year 2024 guidance, lowering expectations from previous projections. The company now anticipates revenues of approximately $180.0 million, down from the previous guidance of $183-189 million, and Adjusted EBITDA of approximately $20.5 million, reduced from the previous $23-28 million range.

New CEO Yogi Jashnani, who recently started his position, outlined plans to stabilize revenue and return to growth by implementing business process changes and enhancing technology usage. The company, which has performed over 70,000 procedures across 32 global centers, aims to leverage its proprietary technology and asset-light business model for long-term profitable growth.

AirSculpt Technologies (NASDAQ: AIRS), a premium body contouring procedures provider, has announced its participation in the upcoming ICR Conference 2025 at The Grande Lakes Orlando in Florida. The event will take place from January 13-14, 2025.

CEO Yogi Jashnani and CFO Dennis Dean will conduct investor meetings and deliver a presentation on January 14, 2025, at 10:00 a.m. EST. The presentation will be accessible via live webcast on the company's investor relations website, with the recording remaining available for 90 days.